NCT03414047 2022-08-19
A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Eli Lilly and Company
Phase 2 Completed
Clinical Trials
8 trialsNCT02124148 2020-04-01
A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02735980 2020-03-17
A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02778126 2019-08-01
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02555644 2019-02-15
A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02860780 2018-12-14
A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02514603 2017-05-22
A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers
Eli Lilly and Company
Phase 1 Completed
NCT01115790 2016-05-10
A Phase 1 Study in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed